Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives $12.60 Consensus Price Target from Analysts

Alpha Tau Medical Ltd. (NASDAQ:DRTS) has earned an average rating of “Hold” from the seven research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $12.60.

Several research firms have recently commented on DRTS. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Barclays upped their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. LADENBURG THALM/SH SH upped their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Citigroup upped their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Finally, Piper Sandler boosted their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th.

Insider Activity

In other news, CFO Raphi Levy sold 32,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total value of $351,975.00. Following the completion of the sale, the chief financial officer owned 147,680 shares of the company’s stock, valued at approximately $1,599,374.40. The trade was a 18.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 39.50% of the company’s stock.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently modified their holdings of the business. Daytona Street Capital LLC acquired a new stake in shares of Alpha Tau Medical in the fourth quarter valued at approximately $749,000. Apella Capital LLC acquired a new stake in shares of Alpha Tau Medical in the fourth quarter valued at approximately $1,892,000. Levin Capital Strategies L.P. raised its position in shares of Alpha Tau Medical by 6.3% in the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after buying an additional 12,200 shares in the last quarter. Millennium Management LLC raised its position in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares in the last quarter. Finally, Mariner LLC raised its position in shares of Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after buying an additional 1,915 shares in the last quarter. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Trading Up 1.8%

Shares of Alpha Tau Medical stock opened at $9.78 on Friday. The business has a fifty day simple moving average of $9.06 and a two-hundred day simple moving average of $7.37. Alpha Tau Medical has a 1 year low of $2.85 and a 1 year high of $11.62. The company has a market capitalization of $883.43 million, a price-to-earnings ratio of -14.60 and a beta of 1.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Research analysts forecast that Alpha Tau Medical will post -0.67 EPS for the current year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.